FDA approves Roche’s Wilserdly for ESR1-mutated advanced breast cancer
The U.S. Food and Drug Administration on Monday approved Roche’s Wilserdly, also known as giredestrant, clearing the Swiss company to launch a breast cancer medicine it has said could become its top-selling product. The decision was among the most important regulatory outcomes Roche had been waiting for and gives it another foothold in a field where it once led through Genentech’s Herceptin, even as it has lately lagged rival drugmakers in oncology.
The approval covers patients with HR-positive, HER2-negative advanced breast cancer whose tumors have an ESR1 mutation, a marker of resistance to standard endocrine therapy. Wilserdly is an oral selective estrogen receptor degrader, or SERD. In the evERA trial it lengthened the time before patients’ tumors progressed, supporting use in this genetically defined group after resistance has emerged.
Continue in the app — vote & join in ➔